Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Eur Rev Med Pharmacol Sci ; 26(6): 2201-2214, 2022 03.
Article in English | MEDLINE | ID: covidwho-1776800

ABSTRACT

Disruption of intracellular Ca2+ homeostasis plays an important role as an upstream pathology in Alzheimer's disease (AD), and correction of Ca2+ dysregulation has been increasingly proposed as a target of future effective disease-modified drugs for treating AD. Calcium dysregulation is also an upstream pathology for the COVID-19 virus SARS-CoV-2 infection and replication, leading to host cell damage. Clinically available drugs that can inhibit the disturbed intracellular Ca2+ homeostasis have been repurposed to treat COVID-19 patients. This narrative review aims at exploring the underlying mechanism by which lithium, a first line drug for the treatment of bipolar disorder, inhibits Ca2+ dysregulation and associated downstream pathology in both AD and COVID-19. It is suggested that lithium can be repurposed to treat AD patients, especially those afflicted with COVID-19.


Subject(s)
Alzheimer Disease , COVID-19 , Alzheimer Disease/drug therapy , Alzheimer Disease/metabolism , COVID-19/drug therapy , Humans , Lithium/therapeutic use , Lithium Compounds/therapeutic use , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL